Ponatinib-associated panniculitis: Case report and review of the literature

Ponatinib-associated panniculitis: Case report and review of the literature

Ponatinib is a tyrosine kinase inhibitor (TKI) approved for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia and acute lymphoblastic leukemia. Common adverse effects of ponatinib include neutropenia, arterial thrombosis, and hypertension. We describe a 49-year-old woman...

Full description

Bibliographic Details
Main Authors: Daniel Antwi-Amoabeng, Joban Ghuman, Jasmine Ghuman, Bryce D. Beutler, Mark B. Ulanja, Kevin Kuriakose, Aaron Bowman
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Adverse drug reactions
ALL
CML
Panniculitis ponatinib
Tyrosine kinase inhibitors
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294221000551

Internet

http://www.sciencedirect.com/science/article/pii/S2468294221000551

Similar Items